Aspire Biopharma Holdings, Inc. (ASBP) Stock Price & Analysis
Aspire Biopharma Holdings, Inc. (ASBP) rose 0.69% to USD 7.26 as of July 25, 2026 at 09:07 UTC, according to Nexqual real-time market data.
ASBP last closed at USD 7.21; the session ranged USD 7.01–7.37 on volume of 28,092 shares. Market capitalization is $9.40M, with a 52-week range of USD 0.11–35 (NCM). Source: Nexqual, July 25, 2026 at 09:07 UTC.
Key Statistics (as of July 25, 2026 at 09:07 UTC)
| Price | USD 7.26 |
|---|---|
| Change | ▲ 0.69% (up) |
| Previous Close | USD 7.21 |
| Open | USD 7.12 |
| Day Range | USD 7.01 – 7.37 |
| 52-Week Range | USD 0.11 – 35 |
| Volume | 28,092 shares |
| Market Cap | $9.40M |
| Exchange | NCM |
Technical Analysis (ASBP)
Nexqual's technical model rates ASBP "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 09:07 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 61.74 (neutral) |
| vs SMA50 | Above (USD 6.03) |
| MACD | 0.45 (positive) |
Analyst Ratings (ASBP)
Wall Street analysts rate ASBP "None", per Nexqual as of July 25, 2026 at 09:07 UTC.
| Consensus Rating | None |
|---|
Earnings (ASBP)
Source: Nexqual, July 25, 2026 at 09:07 UTC.
Financials & Fundamentals (ASBP)
| Total Revenue | $34,555 |
|---|---|
| Gross Margin | +16.30% |
| Operating Margin | -5758.70% |
| Profit Margin | +0.00% |
| Debt / Equity | 38.76 |
| Current Ratio | 2.26 |
| Total Cash | $5.86M |
| Total Debt | $1.50M |
| Free Cash Flow | $-1.02M |
Source: Nexqual, July 25, 2026 at 09:07 UTC.
Financial Health Score (ASBP)
Nexqual rates Aspire Biopharma Holdings, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 09:07 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $6M cash vs $1M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$1M, burning cash |
| Efficiency | Mixed — No data |
Ownership (ASBP)
| Insider Ownership | +5.91% |
|---|---|
| Institutional Ownership | +0.99% |
| Shares Outstanding | 1.30M |
| Float | 1.22M |
| Short % of Float | +9.20% |
Source: Nexqual, July 25, 2026 at 09:07 UTC.
Leadership (ASBP)
Aspire Biopharma Holdings, Inc. is led by Kraig T. Higginson (age 69), Interim CEO, President & Executive Chairman of the Board, per Nexqual as of July 25, 2026 at 09:07 UTC.
| Interim CEO, President & Executive Chairman of the Board | Kraig T. Higginson (age 69) |
|---|---|
| Chief Financial Officer | Ernest J. Scheidemann (age 64) |
Major Backers & Investors (ASBP)
Notable institutional backers of Aspire Biopharma Holdings, Inc. include UBS Group AG, Morgan Stanley, according to Nexqual as of July 25, 2026 at 09:07 UTC.
Active Investors
| Investor | Stake |
|---|---|
| UBS Group AG | 0.49% |
| Morgan Stanley | 0.2% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Geode Capital | 0.11% |
Source: Nexqual, July 25, 2026 at 09:07 UTC.
From Aspire Biopharma Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- We also rely on trade secrets, know-how and continuing technological innovation to develop and maintain our proprietary and intellectual property position.   Any patents granted from national/regional phase applications of International Application No.
- A second patent application was filed in October 2024 for a high-dose version of our sublingually administered aspirin product (application number 63/702,381) using a micelle variation on our technology which can be used with a variety of substances.   In the initial development launch of its aspirin product, Aspire has focused on the delivery of aspirin, which may be the most studied and accepted analgesic and anti-inflammatory drug on the market.
Partnerships
- We have also entered into a manufacturing agreement with Microsize, a contract development and manufacturing organization or ("CDMO") in Quakertown, PA in January 2026 to manufacture aspirin products for the next round of clinical trials of the high-dose aspirin for myocardial infarction.   We used drug product manufactured by Glatt to conduct clinical trials to support approval of a section 505(b)(2) New Drug Application ("NDA") for the aspirin product.
- In addition, we have entered into a fill-and-finish agreement with a contract manufacturer to convert the aspirin product manufactured by Glatt into packaged drug product that can be utilized in clinical trials.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PFSA | Profusa, Inc. | USD 1.71 | ▼ 10% |
| CYCU | Cycurion, Inc. | USD 0.32 | ▲ 3.23% |
| OSRH | OSR Health, Inc. | USD 0.42 | ▼ 3.64% |
| PLRZ | Polyrizon Ltd. | USD 14.68 | ▲ 2.02% |
| AZI | Autozi Internet Technology (Glo | USD 1.16 | ▼ 7.94% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 09:07 UTC. This page is informational and not investment advice.